TransThera Sciences (Nanjing). Inc. (FWB:J8J) Filings

TransThera Sciences (Nanjing). Inc.

Filings

FilingDateTypeFiled with
Next Day Disclosure ReturnNov 19, 2026Next day disclosure returnHKEX
INSIDE INFORMATION ANNOUNCEMENT COMPLETION OF THE H SHARE FULL CIRCULATIONNov 19, 2026Other filingsHKEX
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026Nov 3, 2026Monthly returnHKEX
Next Day Disclosure ReturnNov 2, 2026Next day disclosure returnHKEX
INSIDE INFORMATION ANNOUNCEMENT GRANT OF LISTING APPROVAL BY THE STOCK EXCHANGE FOR IMPLEMENTATION OF THE H SHARE FULL CIRCULATIONNov 1, 2026Other filingsHKEX
Next Day Disclosure ReturnOct 27, 2026Next day disclosure returnHKEX
INSIDE INFORMATION ANNOUNCEMENT ISSUANCE OF THE FILING NOTICE BY THE CSRC FOR THE H SHARE FULL CIRCULATION BY THE COMPANYOct 26, 2026Other filingsHKEX
Next Day Disclosure ReturnOct 26, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnOct 23, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnOct 22, 2026Next day disclosure returnHKEX
VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON COMMERCIALISATION OF CORE PRODUCT YOCHANRAOct 22, 2026Operations updateHKEX
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026Oct 5, 2026Monthly returnHKEX
INTERIM REPORT 2026Sep 21, 2026Interim reportHKEX
VOLUNTARY ANNOUNCEMENT FIRST PATIENT DOSED IN PHASE II CLINICAL TRIAL OF TINENGOTINIB IN COMBINATION WITH NOVEL HORMONAL THERAPY FOR PRETREATED AND PROGRESSED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN CHINASep 18, 2026Operations updateHKEX
VOLUNTARY ANNOUNCEMENT INCLUSION OF YOCHANRA (TINENGOTINIB) IN THE CSCO GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF BILIARY TRACT CANCERS (2026)Sep 18, 2026Other filingsHKEX